Tag Archives: advocacy
Statement by Research!America President and CEO Mary Woolley in Response to President Obama’s FY2016 Budget
We are pleased that the President’s FY16 budget proposal calls for the elimination of sequestration and starts an overdue conversation about better aligning resources for public health and medical progress, given their importance to the American people and to the health of our economy. It is critical that we ramp up initiatives that focus on precision medicine, Alzheimer’s, antimicrobial resistance and other growing health threats, but these investments should supplement, not supplant, the imperative of making up for a decade’s worth of lost ground. We believe that Congress and the White House can, and must, unify behind the vision encapsulated in the bipartisan Accelerating Biomedical Research Act. Medical progress is not just a health imperative, it is a strategic imperative, integral to national security, fiscal stability and economic progress. Leaders on both sides of the aisle clearly appreciate that the time is now to turn ideas into reality. It may be a truism, but where there’s a will, there’s a way. Continue reading →
Statement by Research!America President and CEO Mary Woolley on President Obama’s Precision Medicine Initiative
President Obama’s Precision Medicine Initiative could potentially drive medical and health research into exciting, new territory as we advance efforts to develop the right treatments at the right time for individual patients. A laser-focus approach that takes into account a patient’s genetic profile, environment and lifestyle is critical to treat diseases such as cancer which afflicts millions of Americans. Only about a quarter of Americans believe the U.S. has the best health care system in the world, according to public opinion polling commissioned by Research!America. This initiative could help reverse both the perception and the reality with targeted treatments that will save lives and improve health care delivery.
This initiative is an important development for patients, physicians and researchers who will benefit from a stronger national commitment to precision medicine and for those who may yet take advantage of the new tools and therapies that will result from this effort. And many Americans are ready to support this endeavor. Polls show more than half say they are willing to share their personal health information to advance research and help improve patient care, and a majority believe that elected officials should listen to advice from scientists. This initiative is a major step towards building a stronger public-private partnership to leverage health data and technology to accelerate the discovery and development of tailored treatments for patients. Continue reading →
Dear Research Advocate:
I warn you that today’s letter is long. There is a lot going on; suddenly, lots of people in Congress are staking out leadership roles as champions for research! On Tuesday, the first draft of the much anticipated 21st Century Cures legislation was released. Chairman Fred Upton (R-MI-06) and Congresswoman Diana DeGette (D-CO-01), who will jointly receive Research!America’s 2015 Edwin C. Whitehead Award for Medical Research Advocacy at our Advocacy Awards dinner on Wednesday, March 11 (click here to join us for the event), have been partnering on this effort since last spring. Congresswoman DeGette has not endorsed the current draft, but she has made it clear that she continues to be committed to the process. We are, too. Over the coming weeks, we will be meeting with the 21st Century Cures team and participating in a variety of discussions on the intricacies of the bill.
Among our priorities will be to ensure that basic discovery is not neglected (a house built on sand…), and to make sure that, for the U.S. Food and Drug Administration (FDA) and other agencies – already struggling to fulfill their current responsibilities – if given new “to do” lists, must also be given new resources. We will continue to push for final bipartisan language that effectively boosts the return on medical progress by accelerating discovery, development and delivery. See our statement on the 21st Century Cures release here. And click here to see the Committee’s documents. They have invited suggestions on the draft, and ask that you send your comments to firstname.lastname@example.org. Continue reading →
Dear Research Advocate:
The State of the Union (SOTU) message is the annual opportunity for the President to outline his goals. Read my statement on it here. The SOTU historically provides a platform for the executive and legislative branches to identify commonalities, or sharpen differences. Topics in our sights on which Congress and the Administration can work together should they choose (meaning if their constituents demand it!) include innovation, research and development, and 21st century business success. In his speech and in a more detailed proposal, the President calls for a significant increase in funding for antibiotic discovery, Alzheimer’s research, the BRAIN Initiative and precision medicine. We urge the President and Congress to go further, working together to advance a strategic “moonshot” that re-energizes our national commitment to science, very much including basic science. Basic discovery is truly the foundation for all of our nation’s scientific advances. It’s pretty simple. As Dr. Roger Perlmutter, Executive Vice President at Merck, said this week in The New York Times: “Since we don’t know how the machine [the human body] works, we don’t know what to do when it breaks.”
Investment in basic and clinical research isn’t a “nice to have” proposition; it’s essential, leading as nothing else will, to good news for patients. An op-ed this week from Executive Vice Chancellor for Medical Affairs at the Washington University School of Medicine in St. Louis and Research!America board member Dr. Larry Shapiro discusses the university’s work, funded by the federal government, which has led to advances in early diagnosis of Alzheimer’s before symptoms are perceptible. Continue reading →
Statement by Research!America president and CEO Mary Woolley on President Obama’s State of the Union Speech
In his State of the Union address, President Obama highlighted the important role of research and innovation in growing a more prosperous and healthier nation. We’re excited about the launch of the Precision Medicine Initiative, which comes at a time when the challenge of conquering disease – all along the research spectrum, from discovery to translation to innovation and application – has never been more within our grasp. The inspiring story of William Elder, Jr. a medical school student and cystic fibrosis survivor, shows that science can deliver breakthroughs for patients with cystic fibrosis, cancer, Alzheimer’s and other diseases. The remarkable ability of our nation’s researchers to advance precision medicine to hone targeted treatments to improve individual patient outcomes is a compelling example of what can be accomplished with federal support. We’re getting closer and closer to achieving treatments that save time, save money and save lives because they are right the first time.
We can’t afford to ease up on our commitment to research, to assure we can put a whole range of diseases in the history books. A further reason, noted by the President, is that we need robust funding and policies to ensure we’re not behind the eight ball addressing domestic or global outbreaks like Ebola. Current funding levels for federal health agencies put researchers at an extreme disadvantage in pursuing studies that have the potential to cure disease and improve quality of life, and tax policies have stymied the development of new drugs. Policymakers must pivot from short-sighted thinking to formulating a long-term strategy that will bring new treatments across the finish line and spur growth in quality jobs. We think it’s past time to adopt a national strategy that will assure the U.S. retains its world leadership in science and innovation. A new Blue Ribbon Commission established by Congress to explore how science is perceived by the public will help stimulate a meaningful conversation with Americans about the societal and economic benefits of science. Continue reading →
Today, Research!America urged the 114th Congress to take action on five science priorities in the first 100 days of the legislative session in order to elevate research and innovation on the nation’s agenda:
- Advance the 21st Century Cures Initiative. Spearheaded by Representatives Fred Upton (R-Mich.) and Diana DeGette (D-Colo.),the initiative is a promising step in the right direction, focusing on speeding medical progress from bench-to-bedside by integrating patient perspectives into the regulatory process, modernizing clinical trials, and reducing red tape, among other things.
- Repeal the medical device tax. A provision in the Affordable Care Act, efforts to repeal the medical device tax have garnered bipartisan support as policymakers and industry leaders raise concerns about the tax’s impact on jobs and innovation.
- Enhance and make the R&D tax permanent. The credit, established in 1981, allows companies to deduct certain research expenses, but the short-term extensions have created uncertainty for businesses that rely on long-term planning for research investments.
- Eliminate Sequestration. As part of the 2011 Budget Control Act, sequestration has taken a significant toll on the research ecosystem, forcing institutions to scale back or eliminate important studies and cut jobs. A two-year bipartisan budget deal for FY14 and FY15 reduced the cuts for those years, but the full sequester returns in FY16.
Excerpt of an op-ed by Research!America President and CEO Mary Woolley published in the Huffington Post.
As the new Congress sets priorities, there are strong indications that the political climate is ripe for a surge in science. Bipartisan support for the 21st Century Cures Initiative, a comprehensive study of roadblocks to medical innovation and development of new disease therapies and treatments, is slated to move forward with draft legislation early next year. The measure is expected to address six areas of reform: integrating patients’ perspectives into the regulatory process, modernizing clinical trials, fostering the future of science, investing in advancing research, incentivizing the development of new drugs and devices for unmet medical needs and supporting digital medicine. Research stakeholders ranging from academia to industry to patient groups are working closely with the architects of this initiative, Chairman Fred Upton (R-Mich.) and Rep. Diana DeGette (D-Colo.), to ensure the measure will remove barriers to getting new treatments and cures to patients more quickly.
There is also bipartisan support to reform tax legislation, a light or heavy lift depending on the tax package. All signs point to a repeal of the medical device tax in the new Congress but the jury is still out on whether the R&D tax credit can be made permanent and ultimately whether Congress is ready to tackle tax and entitlement reform overall. A favorable tax climate and strong investments in research are critical to improving our population’s health, boosting the economy and spurring further private sector innovation. With sustained federal funding at risk in a deficit reduction environment, alternative funding models to augment appropriations should be considered including but not limited to a mandatory trust fund dedicated to steady growth in research.
Read the full op-ed here.
Dear Research Advocate:
I don’t always dwell so much on Congress-related actions (or the lack thereof), but this time it’s essential given all the year-end/Congress-end action. So bear with me; it’s important to the future of health and our nation’s prosperity. The “Cromnibus” narrowly passed Congress and has now been signed into law. As I emphasized in last week’s letter, this bill is too little, too late in a multitude of ways, but it’s better than a shutdown, or a year-long continuing resolution. More to the point is that Congress didn’t do better. Members of Congress can allocate more funding to medical research and science and technology broadly. Congress can alter tax and other public policy to more robustly fuel innovation. Taken together, these actions have historically – and can again – grow our still-struggling economy. Along with our partners, all well-aware of the promise of science and of the very real costs of slowing the science enterprise, we will be working in the new year to change the conversation around research and innovation. More to come on that. Continue reading →
A Weekly Advocacy Message from Mary Woolley: This just in: Congress busy meeting long-expired deadlines
Dear Research Advocate:
Congress is working to reach agreement to fund the government for FY15. Recall that the federal fiscal year 2015 began on Oct. 1, but that deadline was not met. Instead, a continuing resolution (CR) was enacted to keep the government from shutting down. Missed deadlines and CRs have now been the pattern of many years’ standing, despite rhetoric about the importance of a “return to regular order.” Instead of regular order we have “kick the can down the road,” again and again.
It seems increasingly likely that Congress’ current appropriations negotiations will produce a hybrid omnibus and CR (a “CRomnibus” for fans of linguistic portmanteau!) which includes all the spending bills for federal funding except those that relate to immigration. (Those accounts will be funded solely on a short term basis in order to afford the new 114th Congress an opportunity to re-evaluate immigration-related funding early next year.) Neither an extension of the full CR nor a CRomnibus will improve the dismal status quo for science funding. Please urge your Member of Congress to pass full appropriations legislation for FY15, rather than another standing-in-place CR, by clicking here. Continue reading →
With the exception of the December run-off in Louisiana and final tallies in a few very close contests, we know the basic political landscape for the next two years. The change is greater than many analysts predicted, although it is not a surprise that the House and the Senate will both be Republican-controlled for the first time in eight years. What does this mean for U.S medical progress and scientific discovery generally? According to our experts at Research!America’s post-election briefing hosted by the AAAS this morning, we can expect some highs and lows in both the “lame-duck” and the next appropriations cycle, with the first seven months of the new year being the limited window of opportunity before most attention turns to the presidential election. Guest speaker David Hawkings, CQ Roll Call senior editor, provided a synopsis of exit polling and voter turnout, which reflected the public’s discontent with the White House and Congress, a continued emphasis on economic concerns, and even splits between Republicans and Democrats on just about every other issue, a combination of factors that doesn’t bode well for bipartisanship generally, much less regular order or major policy changes. In a panel moderated by Rebecca Adams of CQ HealthBeat, Research!America Chair John Porter, Vice Chair Mike Castle, board member Kweisi Mfume and Bart Gordon, all distinguished former Members of Congress, offered predictions on how — or indeed whether — the new Congress will assign a high priority to research moving forward. Congressman Gordon lamented the fact that post-election op-eds and news articles about the agendas of both parties do not mention R&D; there is clearly much more work ahead of us. Continue reading →
Dear Research Advocate:
If you haven’t already heard, “Throwback Thursday” is a weekly social media activity that celebrates unforgettable moments in our lives. Users of Facebook, Twitter or Instagram draw inspiration from old photos of family and friends or landmark events, and talk about them, accompanied by the hashtag #TBT. Wouldn’t it be great if today’s #TBT includes reflections on the impact of medical and health research on our lives and those of our loved ones — especially today, with the mid-term elections coming right up, with so much at stake for future generations?
Consider how far we’ve come in medicine. This week marks the 100th birthday of Dr. Jonas Salk, who gifted us with a polio vaccine. An article in The Guardian detailing Dr. Salk’s determination to eradicate this debilitating condition gives us plenty to reflect upon. Most people my age lived with the threat of polio and knew people with the disease. Another “throwback” is the conversion of HIV/AIDS from a death threat to a manageable chronic disease. In the throes of public fears about Ebola, there are echoes of AIDS. Continue reading →
Dear Research Advocate:
We thought we learned our lesson after 9/11 and anthrax attacks. After the trauma and after fear swept the nation, we invested substantially in “preparedness.” But then we drifted into complacency, and began cutting deeply into the kind of preparedness that is less visible than TSA and drone strikes, but, as Ebola is teaching us now, no less valuable. As mentioned in today’s congressional hearing on the subject, the decade-long pattern of cuts to federal health agencies, as well as to funding for hospital and public health preparedness, has now been revealed to have been short-sighted. (Much of the cutting was carried out over the years as a way to “prioritize” federal spending in the face of today’s presumably more pressing problems, including reducing the federal deficit and debt. If our policymakers were holding true to the financial priority argument, they wouldn’t have short-changed NIH, NSF, FDA and CDC or acted to discourage private sector research and innovation. Medical research to develop treatments that slow the progression and ultimately prevent Alzheimer’s and obesity is the only means we have of preventing an entirely foreseeable explosion in national health spending! Mary Lasker got to the heart of the matter when she said: “If you think research is expensive, try disease.”)
We expect our elected officials to be preparing on all fronts. There will be more Ebolas. That is scary, but it is inevitable. Maybe the next Ebola will take the form of a virus akin to HIV/AIDs or a major act of bioterrorism or a drug-resistant airborne infection. We are a globalized world facing global health threats, and the federal agencies responsible for preventing and responding to these threats must be supported, not politicized, demonized, or starved. Nor should we address one problem by neglecting others, funding Ebola by reducing dollars for research crucial to combating other health threats. Continue reading →
Dear Research Advocate:
The 2014 Nobel Laureates will be announced next week. I hope you will consider amplifying the news via social media, op-eds and letters to the editor. The Nobel prize is so iconic that it provides an entrée to the broader public, one that can be used to connect the dots between the process of scientific discovery, the power of ingenuity, and the role of science in human progress. And if a winner has been funded by a U.S. science agency or company, all the better from an advocacy perspective!
In the years ahead, will the United States be home to more Nobel Laureates in the sciences, or will those honors go to scientists in countries that place a greater emphasis on research and innovation? This chart compares the R&D commitment of 19 Organisation for Economic Co-operation and Development (OECD) nations, the metric being R&D as a percentage of GDP. The next time you are speaking with a member of Congress or his/her staff, you may want to mention that, in relative terms, Estonia assigns a higher priority to R&D than does the United States. Bravo to Estonia, but do we as a nation truly expect to remain a global powerhouse as we drain our own power source? Continue reading →
Dear Research Advocate:
Just when you thought that there is no good news coming from Washington, it looks as though we have a new congressional champion for research. Senator Cory Booker (D-NJ) penned a most welcome op-ed in the Asbury Park Press this week. We trust this is just one way he works to convince his constituents and his fellow lawmakers of the high priority the nation should be assigning to research. Championing research can be a heavy lift, since it’s no secret that some policymakers don’t see why government should have any role in R&D. A recent article in Forbes pushes back. As part of the BRAIN Initiative, the Defense Advanced Research Projects Agency (DARPA) is researching a potential breakthrough in healing. It’s a long-shot, but DARPA is known for supporting long shots that have made major contributions to our lives. If the featured research proves successful, it will revolutionize the ability to help wounded warriors – and all of us – heal. It will easily pay for itself many times over. (Just as the GPS – a long-shot, expensive product of federally-funded research – revolutionized our national defense capabilities and has paid for itself over and over again in commercial application. That’s what federally funded research does. It goes where the free market can’t and mines new territory in science and technology. The private sector takes it from there.) The House and Senate defense appropriations bills would both cut funding for DOD-funded R&D. Has shooting ourselves in the foot become a policymaking imperative? Continue reading →
The Research and Development Efficiency Act (H.R. 5056) is a common-sense piece of legislation aimed at reducing unnecessary red tape that slows and adds needless costs to federally funded research. This bipartisan legislation passed the House unanimously, but the Senate has not yet considered it. The bill would require the White House Office of Science and Technology Policy to establish a task force to recommend reforms aimed at modernizing and streamlining the administrative requirements surrounding federally funded research, helping researchers to optimize the use of awarded funds.
Don’t let H.R. 5056 die in the Senate. We need your help to build momentum for Senate passage so that the President can sign H.R. 5056 into law this year. Urge your Senators to support this important bill today for pragmatic regulation reform tomorrow!